Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 20/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 16/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.71 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29421147 | 1.00 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL23424104 | 0.86 | ADORA2A (0.76) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL406128 | 0.81 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADORA3 | |
| St1535 SCHEMBL29362910 | 0.81 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL409997 | 0.81 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL30578898 | 0.81 | ADORA2A (0.67) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL19463066 | 0.81 | ADORA2A (0.67) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL4467979 | 0.80 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL4454079 | 0.78 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL4564695 | 0.76 | ADORA2A (0.68) | ADORA2AADORA1ADORA2BADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3280414-B1 | ADENOSINE RECEPTOR MODULATORS FOR THE TREATMENT OF CIRCADIAN RHYTHM DISORDERS | UNIV OXFORD INNOVATION LTD (GB) | 2023-08-23 | — | — | EP | claimed |
| US-20210106605-A1 | Adenosine Receptor Modulators for the Treatment of Circadian Rhythm Disorders | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-04-15 | — | — | US | claimed |
| US-20190111069-A1 | Adenosine Receptor Modulators for the Treatment of Circadian Rhythm Disorders | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-04-18 | — | — | US | claimed |
| EP-3280414-A1 | ADENOSINE RECEPTOR MODULATORS FOR THE TREATMENT OF CIRCADIAN RHYTHM DISORDERS | Oxford University Innovation Limited (GB) | 2018-02-14 | — | — | EP | claimed |
| WO-2017178820-A1 | ADENOSINE RECEPTOR MODULATORS FOR THE TREATMENT OF CIRCADIAN RHYTHM DISORDERS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2017-10-19 | — | — | WO | claimed |
| US-20160002244-A1 | OXIDATED DERIVATIVES OF TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2016-01-07 | — | — | US | claimed |
| EP-2408775-B1 | OXIDATED DERIVATIVES OF TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTS | SIGMA TAU IND FARMACEUTI (IT) | 2015-06-17 | — | — | EP | claimed |
| US-20120053191-A1 | OXIDATED DERIVATIVES OF TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTS | ALFASIGMA S.P.A. (IT) | 2012-03-01 | — | — | US | claimed |
| EP-2408775-A1 | OXIDATED DERIVATIVES OF TRIAZOLYPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTS | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2012-01-25 | — | — | EP | claimed |
| WO-2010106145-A1 | OXIDATED DERIVATIVES OF TRIAZOLYPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-09-23 | — | — | WO | claimed |
| US-12037378-B2 | Variant CD58 domains and uses thereof | NOVARTIS AG (CH) | 2024-07-16 | — | — | US | disclosed |
| US-12037378-B2 | Variant CD58 domains and uses thereof | NOVARTIS AG (CH) | 2024-07-16 | — | — | US | disclosed |
| US-11931374-B2 | Adenosine receptor modulators for the treatment of circadian rhythm disorders | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2024-03-19 | — | — | US | disclosed |
| US-20240025993-A1 | CD19 BINDING MOLECULES AND USES THEREOF | NOVARTIS AG (CH) | 2024-01-25 | — | — | US | disclosed |
| US-20240025993-A1 | CD19 BINDING MOLECULES AND USES THEREOF | NOVARTIS AG (CH) | 2024-01-25 | — | — | US | disclosed |
| US-9133197-B2 | Oxidated derivatives of triazolylpurines useful as ligands of the adenosine A2A receptor and their use as medicaments | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2015-09-15 | — | — | US | disclosed |
| EP-2408775-B1 | OXIDATED DERIVATIVES OF TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTS | SIGMA TAU IND FARMACEUTI (IT) | 2015-06-17 | — | — | EP | disclosed |
| US-20120053191-A1 | OXIDATED DERIVATIVES OF TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTS | ALFASIGMA S.P.A. (IT) | 2012-03-01 | — | — | US | disclosed |
| EP-2408775-A1 | OXIDATED DERIVATIVES OF TRIAZOLYPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTS | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010106145-A1 | OXIDATED DERIVATIVES OF TRIAZOLYPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037378-B2 | Variant CD58 domains and uses thereof | CD2, CD58, CD2BP2 | ADORA2A 725/4885ADORA1 1934/4885ADORA2B 864/4885 |
| US-20210106605-A1 | Adenosine Receptor Modulators for the Treatment of Circadian Rhythm Disorders | ADORA2A, ADORA2B, ADORA3 | ADORA2A 1/4885ADORA1 4/4885ADORA2B 2/4885 |
| US-20240025993-A1 | CD19 BINDING MOLECULES AND USES THEREOF | CD22, BCL9, CD2 | ADORA2A 1457/4885ADORA1 3079/4885ADORA2B 895/4885 |
| US-11931374-B2 | Adenosine receptor modulators for the treatment of circadian rhythm disorders | ADORA2A, ADORA2B, ADORA3 | ADORA2A 1/4885ADORA1 4/4885ADORA2B 2/4885 |
| US-20120053191-A1 | OXIDATED DERIVATIVES OF TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTS | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA1 3/4885ADORA2B 4/4885 |
| US-20190111069-A1 | Adenosine Receptor Modulators for the Treatment of Circadian Rhythm Disorders | ADORA2A, ADORA2B, ADORA3 | ADORA2A 1/4885ADORA1 4/4885ADORA2B 2/4885 |
| US-20160002244-A1 | OXIDATED DERIVATIVES OF TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTS | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA1 3/4885ADORA2B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.